Clinical applications of thrombolytic therapy for arterial and graft occlusion

Intraoperative management: peripheral vascular surgery

Lower extremity atherosclerotic disease affects nearly 10 million people in the United States. Recent advances in diagnostic imaging and interventional techniques help many patients avoid more invasive surgical procedures. Those reaching the operating room, however,represent a distilled subset of patients who are prone to significant comorbidities. We outline current treatment strategies and discuss anesthetic concerns and techniques for these complex patients.

Management strategy for compartment syndrome of the upper extremity arising during anticoagulation or thrombolytic therapy: an increasingly common surgical dilemma

Compartment syndrome is a documented and potentially lethal complication of thrombolytic therapy. With the increasing use of catheter-directed thrombolytic therapy, a high index of suspicion for the potential occurrence of this surgical emergency must be maintained. Errors of omission in the diagnosis of compartment syndrome, even for a few hours, may lead rapidly to limb loss, renal failure, and possibly death. The authors present a case of compartment syndrome arising in the forearm of a patient being treated with continuous catheter-directed thrombolytic therapy for an occluded arterial bypass graft associated with an ischemic lower extremity. Specific to this presentation is their management of compartment syndrome during thrombolytic therapy as well as previously unreported use of a homograft (cadaveric skin) to control ongoing blood loss from a fasciotomy site in this fully anticoagulated patient. The authors think their management in this case may help to provide direction to others faced with a similar, increasingly common, surgical dilemma.

The management of acute limb ischemia: techniques for dealing with thrombus

Acute limb ischemia (ALI) has long been a major clinical problem, producing significant risks for limb loss and death. It is most commonly caused by arterial thrombosis in the setting of underlying atherosclerotic peripheral vascular disease or by arterial embolism, usually of cardiac origin. Over the past several decades, preferred treatment options for ALI have alternated between medical and surgical approaches. More recently, direct intra-arterial thrombolysis became the standard of care after several randomized trials demonstrated the benefit of this approach as compared with acute surgical intervention. Despite all of the experience with direct intra-arterial thrombolysis for the treatment of ALI, the optimal thrombolytic approach not been clearly established. Current investigation is directed at identifying the ideal thrombolytic agent for this purpose and the appropriate dosing regimen. In addition, there is interest in the newer mechanical thrombectomy devices and the use of platelet glycoprotein IIb/IIIa inhibitors to speed the time to reperfusion of the acutely ischemic limb.

Cerebral hemorrhagic complications of thrombolytic therapy

Thrombolytic therapy is well established in the management of a select group of atherothrombotic and thromboembolic diseases at the expense of definite but increased risk of intracranial hemorrhage. The incidence of intracranial hemorrhage is higher (6.4% to 20%) in the thrombolytic treatment of acute ischemic stroke, whereas the cerebral hemorrhagic complications of thrombolytic treatment in acute myocardial infarction, acute pulmonary embolism, deep venous thrombosis, and arterial and graft occlusion is less than 2%. Although systemic fibrinolysis after thrombolysis is responsible for hemorrhagic complications, many factors are implicated in predisposition to cerebral hemorrhagic complications such as old age, untreated or chronic hypertension, history of cardiac disease, hyperglycemia, patients with small body mass, previous stroke, longer therapeutic treatment window, increasing neurological deficit or severity of neurological deficit, higher thrombolytic dose and computed tomography findings of mass effect, edema, or extended infarct sign involving more than one third of the territory of the middle cerebral artery. Although the knowledge of different factors associated with intracranial hemorrhage is important, it is the judicious use and strict adherence of appropriate clinical protocols in different clinical settings of thrombolytic treatment and avoidance of the contra-indications that will minimize the rate of hemorrhagic complication to achieve good clinical outcome and desired benefit.